JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 33–38
Sodium Deoxyribonucleate Prevents Radiation Cystitis in Uterine or Cervical Cancer Patients
P.I. Skopin1, A.A. Ivashin1, Yu.A. Skopina1, Yu.V Kozina 2, R. A. Zukov 2,3 , A.V. Siprov1, E.V. Slepov2
1N.P. Ogarev National Research Mordovia State University, Saransk, Russia.
2A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncological Dispensary, Krasnoyarsk, Russia
3V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia
Contact person: Artem Aleksandrovich Ivashin: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Results: To develop a method for reducing the frequency and severity of early radiation reactions in patients with cancer of the uterus or cervix.
Material and methods: We analyzed the results of treatment of 60 patients with cancer of the uterus and cervix, patients received a postoperative course of external beam radiotherapy combined with the intramuscular administration of the Derinat® radioprotector (sodium deoxyribonucleate); in the second arm, they received a postoperative course of external beam radiotherapy and standard therapy in case of radiation cystitis. The assessment of radiation reactions severity was performed with the EORTC QLQ-C30 criteria, WBC count, IPSS scale, urine analysis and cystoscopic examination evaluated with the developed by us scale.
Results: Evaluation of the quality of life in patients with cervical or uterine cancer at the final stage of treatment using the IPSS scale showed that in the arm of patients with sodium deoxyribonucleate, there was a 30.4 % (p> 0.05) decrease in the symptoms of urinary disorders. The use of the radioprotector sodium deoxyribonucleate also statistically significantly reduced the incidence of radiation cystitis by 73 %. According to cystoscopy, the total bladder injury score at the end of treatment was 147 % lower. The number of leukocytes in the urine analysis at the end of treatment was 116.3 % lower (p≤0.01) in those who received sodium deoxyribonucleate
Conclusion: The data obtained indicate the radioprotective efficacy of sodium deoxyribonucleate and make it possible to recommend its intramuscular administration to patients with cancer of the uterus and cervix against the background of external beam radiation therapy to reduce the frequency and severity of acute radiation cystitis in patients with cancer of the uterus or cervical cancer receiving external beam radiation therapy.
Key words: radiation cystitis, uterine cancer, cervical cancer, sodium deoxyribonucleate
For citation: Skopin PI, Ivashin AA, Skopina Yu.A, Kozina YuV, Zukov R A. Siprov AV, Slepov EV. Sodium Deoxyribonucleate Prevents Radiation Cystitis in Uterine or Cervical Cancer Patients. Medical Radiology and Radiation Safety. 2021;66(5):30-35.
DOI: 10.12737/1024-6177-2021-66-5-33-38
References
1. Eds. Kaprin AD, Starinskiy VV, Shahzadova AO. The Status of Cancer Care for the Population of Russia in 2019. Moscow, Herzen Moscow Scientific Research Institute of Oncology (MNOI) Publ., 2020. 239 p. (In Russian).
2. Bouchard M, Nadeau S, Gingras L, Raymond P, Beaulieu F, Beaulieu L, Germain I. Clinical Outcome of Adjuvant Treatment of Endometrial Cancer Using Aperture-Based Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics. 2008;71;5:1343–1350. DOI:10.1016/j.ijrobp .2007.12.004.
3. Shakespeare TP, Lim KH, Lee KM, Back MF, Mukherjee R, Lu JD. Phase II Study of the American Brachytherapy Society Guidelines for the Use of High-Dose Rate Brachytherapy in the Treatment of Cervical Carcinoma: Is 45–50.4 Gy Radiochemotherapy Plus 31.8 Gy in Six Fractions High-Dose Rate Brachytherapy Tolerable? Int. J. Gynecol. Cancer. 2006;16; 1:277–282.
4. Yalman D, Arican A, Ozsaran Z, Celik OK, Yurut V, Esassolak M., et al. Evaluation of Morbidity after External Radiotherapy and Intracavitary Brachytherapy in 771 Patients with Carcinoma of the Uterine Cervix or Endometrium. Eur. J. Gynaecol. Oncol. 2002;23;1:58–62.
5. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The Impact of Overactive Bladder, Incontinence and Other Lower Urinary Tract Symptoms on Quality of Life, Work Productivity, Sexuality and Emotional Well-Being in Men and Women: Results from the EPIC Study. BJU Int. 2008;101; 11:1388–1395.
6. Jereczek-Fossa BA, Badzio A, Jassem J. Factors Determining Acute Normal Tissue Reactions During Postoperative Radiotherapy in Endometrial Cancer: Analysis of 317 Consecutive Cases. Radiother. Oncol. 2003;68;1:33–39.
7. Nordling J, Fall M, Hanno P. Global Concepts of Bladder Pain Syndrome (Interstitial Cystitis). World Journal of Urology. 2011;30;4:457–464. doi:10.1007/s00345-011-0785-x.
8. Pavlidakey PG, MacLennan GT. Radiation Cystitis. The Journal of Urology. 2009;182;3:1172–1173. doi:10.1016/j.juro.2009.06.034.
9. Sycheva IV, Pasov VV, Kurpesheva AK. Conservative Methods of Treatment of Local Radiation Injuries Formed as a Result of Combined Radiotherapy and Brachytherapy of Prostate Cancer. Siberian Journal of Oncology. 2012;53;5:57-60 (In Russian).
10. Kulaev MT, Almyashev AZ, Meltsaev GG, Shchukin S.A. External1. Application of Derinat in the Treatment of Radiation Ulcers and Malignant Tumors of Visible Localizations. Creative Surgery and Oncology. 2009;1:35-39 (In Russian).
11. Zukov RA, Kozina YV, Kozin VA, Slepov EV. Optimization of Radiation Therapy in Patients with Prostate Cancer. Siberian Medical Review. 2018;2:110-105. DOI: 10.20333/2500136-2018-2-100-105 (In Russian).
12. Minaev NN, Ivanova MN, Bugrimov DY, Klimovich AA. Clinical Efficacy of Agonist Toll-Like Receptor 9 on the Process of Reparations after Loop Conization (LEEP) of the Cervix. Journal of Obstetrics and Women’s Diseases. 2016;5:101-112. DOI: 10.17816/JOWD655101-112 (In Russian).
13. Filatov OY, Kashaeva OV, Bugrimov DYu., Klimovich AA. Morphophysiological Principles of the Immunological Action of Eukaryotic DNA. Russian Journal of Immunology. 2013;7;16:385-390 (In Russian).
14. Kaplina EN. Derinat is a Domestic Natural Immunomodulator. Advances in Current Natural Science. 2003;5:63-64 (In Russian).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors
Article received: 17.02.2021.
Accepted for publication: 20.04.2021.